Pyxis Oncology, Inc. (PYXS) Return on equity 2024–2025
Pyxis Oncology, Inc. (PYXS) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-149.1%FY2025 · since FY2024: -64.0% → -149.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -149.1% | -85.0 pp |
| FY2024 | -64.0% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More PYXS financial trends
PYXS RevenuePYXS Net incomePYXS Net marginPYXS Gross profitPYXS Gross marginPYXS Operating incomePYXS Operating marginPYXS Operating cash flowPYXS Free cash flowPYXS Capital expendituresPYXS Stock buybacksPYXS Dividends paidPYXS Total assetsPYXS Total liabilitiesPYXS Shareholders’ equityPYXS overview →